Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. More Details
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Abcam's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABC is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ABC's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ABC underperformed the UK Biotechs industry which returned 37.3% over the past year.
Return vs Market: ABC underperformed the UK Market which returned 21.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Abcam's share price compared to the market and industry in the last 5 years?
Simply Wall St News
23 hours ago | Simply Wall StAbcam (LON:ABC) Shareholders Have Enjoyed A 87% Share Price Gain
1 month ago | Simply Wall StShareholders Will Probably Be Cautious Of Increasing Abcam plc's (LON:ABC) CEO Compensation At The Moment
2 months ago | Simply Wall StNeed To Know: Abcam plc (LON:ABC) Insiders Have Been Buying Shares
Is Abcam undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ABC (£14.23) is trading above our estimate of fair value (£12.58)
Significantly Below Fair Value: ABC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ABC is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ABC is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ABC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ABC is good value based on its PB Ratio (5x) compared to the GB Biotechs industry average (5.6x).
How is Abcam forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).
Earnings vs Market: ABC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ABC's is expected to become profitable in the next 3 years.
Revenue vs Market: ABC's revenue (11.7% per year) is forecast to grow faster than the UK market (4.7% per year).
High Growth Revenue: ABC's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABC's Return on Equity is forecast to be low in 3 years time (8%).
How has Abcam performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABC is currently unprofitable.
Growing Profit Margin: ABC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ABC is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare ABC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.8%).
Return on Equity
High ROE: ABC has a negative Return on Equity (-0.3%), as it is currently unprofitable.
How is Abcam's financial position?
Financial Position Analysis
Short Term Liabilities: ABC's short term assets (£307.5M) exceed its short term liabilities (£55.1M).
Long Term Liabilities: ABC's short term assets (£307.5M) exceed its long term liabilities (£138.0M).
Debt to Equity History and Analysis
Debt Level: ABC is debt free.
Reducing Debt: ABC had no debt 5 years ago.
Debt Coverage: ABC has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ABC has no debt, therefore coverage of interest payments is not a concern.
What is Abcam current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: ABC is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABC's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alan Hirzel (53 yo)
Mr. Alan Thomas Hirzel, BS, MS, MBA, has been the Chief Executive Officer of Abcam Plc since September 8, 2014 and its Executive Director since January 30, 2014. Mr. Hirzel served as the Chief Marketing Of...
CEO Compensation Analysis
Compensation vs Market: Alan's total compensation ($USD2.22M) is above average for companies of similar size in the UK market ($USD1.68M).
Compensation vs Earnings: Alan's compensation has been consistent with company performance over the past year.
Experienced Management: ABC's management team is seasoned and experienced (5.6 years average tenure).
Experienced Board: ABC's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.
Abcam plc's company bio, employee growth, exchange listings and data sources
- Name: Abcam plc
- Ticker: ABC
- Exchange: AIM
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£3.221b
- Shares outstanding: 226.33m
- Website: https://www.abcam.com
Number of Employees
- Abcam plc
- Discovery Drive
- Cambridge Biomedical Campus
- CB2 0AX
- United Kingdom
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/04 21:43|
|End of Day Share Price||2021/08/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.